AUSTRALIA'S #1 ONLINE CPD EDUCATION PLATFORM

Rethinking first injectable therapies in type 2 diabetes: A practical approach

You need to login to participate in this education.

Please log in, or if you don't already have a free account, register to continue.

This education is accredited: RACGP 40 CPD, ACRRM 5 CME PD.

This accredited learning module explores how to initiate injectable therapy in a patient with type 2 diabetes who remains above their glycaemic target despite taking dual or triple oral therapy. The activity works through 3 in-depth case-studies: a patient with uncomplicated T2D, a patient with ASCVD risk, and a patient with established ASCVD.

On completion of this education activity participants will be able to:
  • Apply Australian guidelines for the medical management of type 2 diabetes when making decisions about treatment intensification to injectable therapy in type 2 diabetes.
  • Explain how the decision cycle for patient-centred glycaemic management in type 2 diabetes can be used to help choose a suitable first injectable therapy for a patient with uncontrolled type 2 diabetes.
  • Consider how a patient’s clinical characteristics, including comorbidities, influence the choice of first injectable therapy in type 2 diabetes.
  • Use recommended tools for assessing absolute cardiovascular risk in patients with type 2 diabetes.
  • Explain key differences between the GLP-1 RA class of glucose-lowering agents and insulin in terms of how they impact cardiovascular risk, hypoglycaemia risk, and their side effect profile and contraindications.
This activity is sponsored by Eli Lilly Australia.
Content partners: 
Components
Rethinking first injectable therapies in type 2 diabetes - Predisposing activity
Rethinking first injectable therapies in type 2 diabetes - Module 1 of 3
Rethinking first injectable therapies in type 2 diabetes - Module 2 of 3
Rethinking first injectable therapies in type 2 diabetes - Module 3 of 3
Rethinking first injectable therapies in type 2 diabetes - Reinforcing activity
Rethinking first injectable therapies in type 2 diabetes - Evaluation